Minimal Residual Disease Testing Market Worth $4.45 billion by 2031--Exclusive Report by Meticulous Research® [Yahoo! Finance]
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Yahoo! Finance
Analysis By Offering, Technology (PCR, Flow Cytometry, NGS) Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor) Sample (Blood, Bone Marrow) – Global Forecast to 2031", published by Meticulous Research ® The Minimal Residual Disease Testing Market is projected to reach $4.45 billion by 2031, at a CAGR of 14.6% during the forecast period 2024–2031. The growth of the minimal residual disease testing market is driven by the growing incidence of cancer, the extensive application of MRD testing in cases of hematological malignancies, the high recurrence rates of some cancers, and increasing investments & funding for MRD testing & research. However, stringent regulatory frameworks and the high costs of MRD testing restrain the growth of this market. Download FREE PDF Brochure Of Minimal Residual Disease Testing Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6068 Furthermore, emerging economies, the rising adoption of personalized treatments & tar
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- Preimplantation Genetic Testing Market Set to Reach $1.2 Billion by 2031, Driven by Advances in Genetic Screening and Growing IVF Demand: Market Research Intellect [Yahoo! Finance]Yahoo! Finance
- Illumina announces expansion of TruSight Oncology portfolio [Yahoo! Finance]Yahoo! Finance
- Illumina announces expansion of TruSight Oncology portfolioPR Newswire
- INITIATE Ventures Closes $45 Million to Fund and Co-create Companies at the Intersection of Healthcare, Life Sciences, and TechPR Web
- Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Stephens from $170.00 to $184.00. They now have an "overweight" rating on the stock.MarketBeat
ILMN
Earnings
- 11/4/24 - Beat
ILMN
Sec Filings
- 11/12/24 - Form SC
- 11/7/24 - Form 4
- 11/7/24 - Form 4
- ILMN's page on the SEC website